[{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"HaemaLogiX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaemaLogiX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HaemaLogiX \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"Cartherics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CTH-401","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cartherics \/ Undisclosed"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ SHINE Technologies"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Vivesto","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Divestment","leadProduct":"Cantrixil","moa":"SMETI","graph1":"Oncology","graph2":"Preclinical","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kazia Therapeutics \/ Vivesto","highestDevelopmentStatusID":"4","companyTruncated":"Kazia Therapeutics \/ Vivesto"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Vivesto is currently exploring TRX-E-002-1 (cantrixil), a potent and selective third generation benzopyran SMETI inhibitor, preclinically for the treatment of hematological cancers.

                          Product Name : TRXE-002-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 31, 2025

                          Lead Product(s) : Cantrixil

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Vivesto

                          Deal Size : $1.0 million

                          Deal Type : Divestment

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Kazia receives an exclusive, worldwide, licence for the development of any drugs, including GDC-0084 (paxalisib) within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.

                          Product Name : GDC-0084

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 09, 2024

                          Lead Product(s) : Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : QIMR Berghofer Medical Research Institute

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The funding will support the clinical trial for CTH-401, the Company’s lead cell therapy and the only natural killer (NK) cell product currently under development for ovarian cancer.

                          Product Name : CTH-401

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 30, 2024

                          Lead Product(s) : CTH-401

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $15.0 million

                          Deal Type : Private Placement

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                          Product Name : PRP

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 22, 2024

                          Lead Product(s) : Chymotrypsinogen,Trypsinogen

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells.

                          Product Name : PRP

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 15, 2023

                          Lead Product(s) : Chymotrypsinogen,Trypsinogen

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DR...

                          Product Name : Deflexifol

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          July 31, 2023

                          Lead Product(s) : Fluorouracil,Calcium Folinate,Oxaliplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Allarity Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The partnership aims for Propanc's lead product candidate, PRP (pancreatic proenzyme), a mixture of two proenzymes, trypsinogen and chymotrypsinogen, advancing towards a Phase I, first-in-human study in advanced cancer patients.

                          Product Name : PRP

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          June 06, 2023

                          Lead Product(s) : Chymotrypsinogen,Trypsinogen

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Peter MacCallum Cancer Centre

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.

                          Product Name : AMP945

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 29, 2023

                          Lead Product(s) : AMP945,Fluorouracil,Calcium Folinate

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Anti-KMA CAR-T is a myeloma-specific antigen not found on normal cells. It has completed preclinical studies and is being developed to treat kappa-type multiple myeloma.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 27, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products including RAD206. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.

                          Product Name : RAD206

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 19, 2022

                          Lead Product(s) : n.c.a. 177-Lu

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : SHINE Technologies

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank